Loading
NASDAQHealthcareBiotechnology
Latest quote
$23.64
−$0.87 · -3.55%
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Previous close
$23.64
−$0.87 · -3.55%
After-hours
$23.64
$0.00 · 0.00%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Day range
Current $23.64
52-week range
Current $23.64
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
38
Expensive
Sentiment
56
Mixed
Risk
52
Elevated Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Day range
Current $23.64
52-week range
Current $23.64
| Metric (USD) | FY2025 |
|---|---|
| Revenue | 2.98M USD |
| Gross profit | 2.98M USD |
| Research and development | 126.62M USD |
| Selling, general, and administrative | 37.52M USD |
| Operating expenses | 164.13M USD |
| Interest income | 6.35M USD |
| Interest expense | 17K USD |
| Depreciation and amortization | 4.91M USD |
| Operating income | −161.16M USD |
| Net income | −148.65M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$38.00
60.74% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.05M0.00%2.3T USD0.03%$373.24-0.62%
Vanguard Extended Market ETFVXF3.4M0.00%93.7B USD0.05%$236.16-1.05%
Schwab U.S. Small-Cap ETFSCHA1.8M0.01%22.62B USD0.03%$33.65-1.32%
Schwab U.S. Broad Market ETFSCHB309.18K0.00%44.34B USD0.03%$29.23-0.58%
Vanguard Russell 2000 ETFVTWO224.95K0.00%17.4B USD0.06%$116.34-1.00%
Vanguard Russell 2000 Growth ETFVTWG22.13K0.00%1.7B USD0.06%$266.89-1.41%
Vanguard Russell 2000 Value ETFVTWV8.29K0.00%1.4B USD0.06%$193.13-0.67%
Vanguard Russell 3000 ETFVTHR3.69K0.00%6.1B USD0.06%$334.21-0.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHASchwab U.S. Broad Market ETFSCHBVanguard Russell 2000 ETFVTWOVanguard Russell 2000 Growth ETFVTWGVanguard Russell 2000 Value ETFVTWVVanguard Russell 3000 ETFVTHRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
